VILOXAZINE

Course overview

VILOXAZINE WAS MARKETED AS AN ANTIDEPRESSANT, IN EUROPE, FOR OVER TWO DECADES PRIOR TO BEING PROPOSED AS A POTENTIAL TREATMENT FOR PATIENTS WITH ADHD (ATTENTION DEFICIT HYPERACTIVITY DISORDER). IN 1971, VILOXAZINE WAS FIRST ENDORSED IN THE UNITED KINGDOM BEFORE BEING RECOGNIZED BY NUMEROUS OTHER NATIONS AS AN ANTIDEPRESSANT. IN APRIL OF 2021, THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) APPROVED THE USE OF VILOXAZINE IN CHILDREN AND ADOLESCENTS WITH ADHD, SPECIFICALLY VILOXAZINE EXTENDED-RELEASE CAPSULES (1). THIS ACTIVITY SUMMARIZES THE INDICATIONS, ADMINISTRATION, DOSES, CONTRAINDICATIONS, ACTIVITY, ADVERSE EVENTS, AND OTHER CRITICAL ELEMENTS OF VILOXAZINE THERAPY IN THE CLINICAL SETTING RELATED TO THE CRUCIAL POINTS REQUIRED BY MEMBERS OF AN INTERPROFESSIONAL TEAM MANAGING THE CARE OF PATIENTS WITH ADHD.